General Information
Cidara Influenza CD388.SQ.2.05
A Phase 2b Randomized, Double-blind, Placebo-controlled, Multicenter Dose Ranging Study to Evaluate Efficacy and Safety of CD388, a Novel Long-acting Antiviral Conjugate, for the Prevention of Influenza in Subjects not at Risk for Influenza Complications
| Protocol | CD388.SQ.2.05 |
|---|---|
| Identifier | |
| UID | a903e973-bc03-459a-91f5-f669d6d74de7 |
| Status | Pending Closeout |
| Phase | 2b |
| Category | Influenza / Adult |
| Launch Year | 2024 |
| NCT Number | - |
| Created | 2024-07-30 11:22 |
| Last Updated | 2025-09-02 20:40 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2024-12-04 | No |
| Enrollment Open | 2024-10-04 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2024-09-23 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2025-10-01 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | Gomez, Kathie | KGomez | No |
| Coordinator | Loera, Yazmin | YLoera | No |
| Regulatory | Romero, Araselly | ARomero | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Cidara Therapeutics |
|---|---|
| Division | Cidara Therapeutics |
| Team | Cidara Therapeutics |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | Parexel International |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | LightSkyBlue |
| Currency | - |
